Norwood, Mass.
Moderna Therapeutics began construction in October of 2016 on a $110 million clinical manufacturing facility in Norwood, Mass. Designed to meet current GMP and GLP standards, the 200,000-sf center will support the production of messenger RNA (mRNA) therapies and vaccines. DPS is providing architectural, engineering, construction management, commissioning, qualification, validation, and procurement services for the project. The clinical labs, offices, and ancillary spaces are being designed by TRIA. Completion is expected in early 2018.
